Literature DB >> 1672923

Postmenopausal oestrogen and cardioprotection.

J P Vandenbroucke1.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1672923     DOI： 10.1016/0140-6736(91)92526-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

Review 1.  Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits.

Authors:  M K Goddard
Journal:  Br J Gen Pract       Date:  1992-03       Impact factor: 5.386

2.  Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.

Authors:  C C Chiueh; T Andoh; A R Lai; E Lai; G Krishna
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

Authors:  J A Kanis
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

4.  Women need to be fully informed about risks of hormone replacement therapy.

Authors:  E H Price; H K Little
Journal:  BMJ       Date:  1996-05-18

Review 5.  Hormone replacement therapy in the aged. A state of the art review.

Authors:  S Jacobs; T C Hillard
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

6.  Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework.

Authors:  H C Wilkes; T W Meade
Journal:  BMJ       Date:  1991-06-01

7.  Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased?

Authors:  W F Posthuma; R G Westendorp; J P Vandenbroucke
Journal:  BMJ       Date:  1994-05-14

8.  Hormone replacement therapy. Should be used selectively.

Authors:  J C Stevenson; M Baum
Journal:  BMJ       Date:  1994-07-16

Review 9.  Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels.

Authors:  A K Mantel-Teeuwisse; J M Kloosterman; A H Maitland-van der Zee; O H Klungel; A J Porsius; A de Boer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.